Cargando…

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC

Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jaejun, Sung, Pil Soo, Yang, Hyun, Lee, Soon Kyu, Nam, Hee Chul, Yoo, Sun Hong, Lee, Hae Lim, Kim, Hee Yeon, Lee, Sung Won, Kwon, Jung Hyun, Jang, Jeong Won, Kim, Chang Wook, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767204/ https://www.ncbi.nlm.nih.gov/pubmed/33371271 http://dx.doi.org/10.3390/jcm9124121

Ejemplares similares

Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
por: Lee, Jaejun, et al.
Publicado: (2021)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2020)

Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis
por: Lee, Sung Won, et al.
Publicado: (2017)

Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin
por: Yoo, Sun Hong, et al.
Publicado: (2020)

Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma
por: Sung, Pil Soo, et al.
Publicado: (2020)

Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Lee, Soon Kyu, et al.
Publicado: (2020)

Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization
por: Lee, Hae Lim, et al.
Publicado: (2019)

A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
por: Lee, Soon Kyu, et al.
Publicado: (2023)

Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus
por: Lee, Hae Lim, et al.
Publicado: (2021)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
por: Lee, Soon Kyu, et al.
Publicado: (2022)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
por: Yang, Hyun, et al.
Publicado: (2017)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
por: Cho, Young Youn, et al.
Publicado: (2021)

Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma
por: Jekarl, Dong Wook, et al.
Publicado: (2019)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies
por: Li, Huichen, et al.
Publicado: (2020)

Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with my- eloproliferative neoplasms
por: Lee, Jaejun, et al.
Publicado: (2020)

Correction: Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma
por: Jekarl, Dong Wook, et al.
Publicado: (2020)

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
por: Ryu, Ji Eun, et al.
Publicado: (2022)

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma
por: Song, Myeong Jun, et al.
Publicado: (2016)

Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
por: Kim, Soon Sun, et al.
Publicado: (2017)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
por: Kim, Ji Hoon, et al.
Publicado: (2023)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy
por: Lee, Hae Lim, et al.
Publicado: (2017)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Reactivation of Hepatitis B Virus in HBsAg-Negative Patients with Hepatocellular Carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2015)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2022)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery
por: Lee, Jun Hee, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a7bjg9on9aql086tcrvvih999f